Synthetic Data for Clinical Research: Ethics and Opportunities

In early 2024, several large hospital systems did something that would have raised serious eyebrows just a few years ago: they trained clinical research models on patient data that did not belong to any real person. No privacy breach followed, no consent forms were violated, and no records were exposed, because there were no actual patients behind the data at all. The datasets looked realistic, behaved like real-world clinical data, and produced statistically valid results, yet they were entirely synthetic.

This shift marks more than a technical milestone. It reflects a growing discomfort with the way modern clinical research depends on real patient data at a time when privacy expectations, regulatory pressure, and public scrutiny have never been higher. Access to high-quality datasets has become one of the industry’s biggest constraints. Consent frameworks are harder to navigate, cross-border data sharing is increasingly restricted, and repeated data misuse scandals have made patients more cautious about how their information is used. At the same time, AI-driven research demands larger, more diverse, and more granular datasets than traditional clinical studies were ever designed to support.

Synthetic data is emerging as an attempt to reconcile these tensions. In theory, it allows researchers to preserve statistical validity while avoiding direct exposure of sensitive patient information. It promises faster iteration, broader collaboration, and better representation of under-studied populations, without the legal and ethical risks tied to real-world records.

But replacing real patients with synthetic ones raises questions that are harder to resolve. Can artificially generated data capture rare events and clinical edge cases? How do biases propagate when synthetic datasets are derived from imperfect originals? And if a model trained on synthetic patients fails in real-world care, who carries responsibility for that failure?

As synthetic data moves from experimental pilots into mainstream clinical research, the conversation can no longer focus only on technical feasibility. The real challenge lies in governance, accountability, and ethical clarity. Synthetic data may reduce privacy risk, but it does not eliminate the need for careful judgment about how evidence is generated and used.

This article examines where synthetic data is genuinely expanding what clinical research can do, where its ethical limits remain, and why its long-term value depends less on clever generation techniques and more on how responsibly the industry chooses to deploy it.

Why Clinical Research Hit a Data Wall and Why Synthetic Data Entered the Conversation

Clinical research did not turn to synthetic data out of curiosity. It turned to it because the traditional data model began to break under its own weight.

Over the past five years, access to real-world clinical data has become slower, more fragmented, and more legally constrained. Privacy regulations tightened across jurisdictions, cross-border data sharing grew increasingly complex, and patient consent models struggled to keep up with secondary uses of data in AI-driven research. At the same time, modern clinical studies started demanding datasets that look very different from what legacy trials were designed to produce: longitudinal, multimodal, and large enough to support machine learning.

This tension is already visible in practice. In the U.S., several pharmaceutical companies have publicly acknowledged delays in early-stage research not because of a lack of interest or funding, but because usable patient-level data could not be accessed fast enough under existing governance frameworks. Even when data exists, negotiating permissions across hospitals, sponsors, and jurisdictions can take longer than the modeling itself.

One concrete example comes from oncology research. Real-world evidence studies increasingly rely on EHR data to complement or replace traditional control arms. However, sharing patient-level oncology data across institutions raises obvious privacy concerns, especially for rare cancers where re-identification risk is higher. To address this, multiple research groups have piloted synthetic datasets that mirror tumor progression patterns, treatment sequences, and outcomes without exposing individual patient records. These datasets are not used to make clinical claims on their own, but they allow teams to prototype analyses, test hypotheses, and validate study designs before touching real patient data.

Another visible use case has emerged in regulatory-facing work. The U.S. Food and Drug Administration has explicitly explored synthetic data as a tool for device and software evaluation, particularly in situations where collecting real patient data at scale is impractical or ethically questionable. In several public workshops and pilot programs, regulators have examined whether synthetic datasets can be used to stress-test algorithms, simulate edge cases, and evaluate performance across populations that are underrepresented in traditional trials.

Synthetic data has also been used to address a quieter problem: bias detection. Some health systems now generate synthetic patient cohorts to audit models for disparities across race, gender, or socioeconomic status without repeatedly exposing sensitive demographic data. By simulating populations that are poorly represented in historical datasets, researchers can identify where models fail before deployment, rather than discovering those failures in live care.

What these cases have in common is modest ambition. Synthetic data is not being positioned as a replacement for clinical trials or real-world evidence. Instead, it functions as an enabling layer - a way to unblock research, test assumptions, and reduce risk before real patients are involved.

This is an important distinction. The most successful applications of synthetic data today treat it as scaffolding, not a foundation. It supports research workflows, accelerates iteration, and improves preparedness, but it does not claim to stand in for reality.

The danger begins when that distinction blurs. As synthetic data becomes easier to generate and more convincing to analyze, the temptation grows to rely on it beyond its safe boundaries. Understanding where those boundaries lie is the ethical challenge that now sits at the center of synthetic data adoption in clinical research.

The Ethical Risk Nobody Likes to Name: When Synthetic Data Creates False Confidence

The most dangerous thing about synthetic data is not that it might be wrong. It is that it can look convincingly right.

Because synthetic datasets are engineered to preserve statistical properties, they often behave exactly as expected. Models train smoothly. Validation curves look clean. Bias metrics improve. From the inside, everything appears more controlled than in the messy world of real patient data. And that is precisely where the ethical risk begins.

Synthetic data does not discover new truth. It reproduces existing patterns, assumptions, and gaps embedded in the original data it was trained on. If rare adverse events were underreported in the source dataset, they will almost certainly be underrepresented in the synthetic one. If certain populations were missing or poorly captured, synthetic generation does not magically restore them; it extrapolates from what it already knows.

This creates a subtle but serious problem in clinical research: the illusion of completeness. Researchers may believe they are stress-testing models across diverse scenarios, when in reality they are reinforcing the same blind spots with greater confidence. The data feels safer, cleaner, and easier to work with, but also more detached from the unpredictable reality of clinical care.

There is also a growing concern around rare conditions and edge cases. Synthetic data performs best where patterns are well-established and abundant. It struggles where medicine struggles most: low-incidence diseases, atypical presentations, and complex comorbidities. In these cases, synthetic patients are often statistically plausible but clinically unconvincing. A model trained on such data may perform well on paper while remaining fragile in real-world deployment.

Another ethical tension lies in responsibility. When real patient data is used, there is an implicit moral contract: these records represent lived experiences, and failures have human consequences. Synthetic data can weaken that sense of accountability. When no real person is directly represented, it becomes easier to treat mistakes as technical rather than ethical failures. Yet when models trained on synthetic data influence clinical decisions, real patients still bear the risk.

There is also a transparency problem. Few patients are aware that models affecting their care may have been trained, tested, or validated on synthetic cohorts. Informed consent frameworks rarely account for this layer of abstraction. The ethical question is not whether patients must approve synthetic data use, but whether they deserve to understand how far removed a model’s “evidence” may be from real human experience.

Perhaps the most uncomfortable issue is how synthetic data reshapes trust. Regulators, investors, and internal review boards may be reassured by privacy-preserving datasets and clean audit trails. But trust built on distance from reality can be brittle. When models fail in practice, the gap between simulated confidence and lived outcome becomes painfully visible.

Synthetic data is often framed as a way to remove ethical risk from clinical research. In reality, it relocates that risk. The challenge is no longer protecting individual privacy alone, but guarding against overconfidence, abstraction, and moral disengagement in how evidence is generated.

Conclusion: Why Synthetic Data Will Reward Discipline, Not Hype

Synthetic data is often framed as a shortcut - a way to bypass privacy constraints, accelerate research, and unlock AI at scale. For investors and founders, that narrative is tempting. But the real opportunity lies elsewhere.

The most durable value in synthetic data will not come from companies that promise to replace real-world evidence, but from those that understand its limits and design around them. Synthetic data works best as infrastructure, not as a headline feature: a way to de-risk early research, accelerate iteration, improve model robustness, and support regulatory readiness without compromising patient trust.

For investors, this creates a clear signal. The strongest teams in this space are not the ones claiming that synthetic data “solves” access to clinical data, but those building governance, validation, and monitoring into the product from day one. The market will increasingly reward startups that can show how synthetic data is used responsibly alongside real-world data, not in isolation from it.

There is also a strategic advantage in timing. As regulators, health systems, and pharmaceutical companies become more cautious about data provenance and model accountability, synthetic data offers a way to move faster without cutting ethical corners. Startups that treat synthetic data as a credibility layer, rather than a growth hack, are better positioned to scale across institutions and borders.

The next phase of clinical research will not be defined by how much data a company has, but by how well it understands the data it generates. Synthetic data, used with discipline and transparency, can be a powerful enabler of that shift. Used carelessly, it becomes another source of overconfidence.

For founders and investors alike, the takeaway is simple: synthetic data is not a substitute for trust. It is a test of whether an organization knows how to earn it.